eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2023
vol. 61
 
Share:
Share:
Original paper

Knockdown of lncRNA BDNF-AS alleviates isoflurane-induced neuro-inflammation and cognitive dysfunction through modulating miR-214-3p

Lin Wang
1
,
Yajun Mao
2, 3
,
Yugang Lu
4
,
Yawei Yuan
5
,
Yanwu Jin
6

  1. Department of Anesthesiology, Guangzhou Red Cross Hospital (Guangzhou Red Cross Hospital of Jinan University), Guangzhou, China
  2. Department of Operating Room, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
  3. Department of Nursing, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
  4. Department of Anesthesiology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
  5. Department of Anesthesiology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
  6. Department of Anesthesiology, The Second Hospital of Shandong University, Shandong University, Jinan, China
Folia Neuropathol 2023; 61 (1): 68-76
Online publish date: 2023/02/17
Article file
- Knockdown.pdf  [0.22 MB]
Get citation
 
PlumX metrics:
 

Introduction

Since great progress has been made in the development of anesthetic agents, anesthesia is an essential process during most surgeries involving a variety of anesthetics, including isoflurane. Isoflurane is a volatile and inhaled anesthetic, which has been applied in clinics for decades. Although isoflurane has been demonstrated to show neurological protective effect during treatment of some diseases, such as intra-cerebral hemorrhage, subarachnoid hemorrhage, and cerebral ischemia-reperfusion [4,13,29], it was also reported to possess neuro-toxicity damaging the recovery and neurological abilities of patients, which is closely correlated with its’ dosage and timing of medication [22]. With the development of molecular biology, identification of effective biomarkers monitoring harmful effect of isoflurane has drawn special attention; it benefitted clinical application of isoflurane and prevented the damaging effect of isoflurane.
Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) are critical members of the non-coding RNA family, which could mediate a series of cellular processes, such as cell growth, differentiation, and metastasis, therefore regulate disease development [20,21]. Previously, some central nervous system-correlated lncRNAs leaked out, which was reported to regulate the progression of neuro-degenerative diseases and exert a protective effect on neurological impairment [25]. Among the dysregulated lncRNA BDNF-AS (BDNF-AS) was a dugout, which was illustrated to participate in the occurrence of Alzheimer’s and Parkinson’s diseases that were associated with neurological injury [8,9]. Although few data are available to evidence the specific function of BDNF-AS in isoflurane-induced neuro-toxicity, it was considered to possess great potential to regulate nerve damage caused by isoflurane. As the down-stream target of BDNF-AS, miR-214-3p was suggested to regulate the autophagy and apoptosis pathways, and therefore mediate neurological disorders [2,30]. In addition, miR-214-3p was revealed to mediate the modulatory effect of lncRNA BACE1-AS1 in isoflurane-induced neuro-toxicity, implying its’ potential in mediating the effect of BDNF-AS1 on isoflurane-induced neurological impairment [11].
This study aimed to investigate the role of BDNF-AS/miR-214-3p axis in isoflurane-induced neurological injury, and to provide a novel insight into the nerve damage resulting from anesthetic.

Material and methods

Cell culture and transfection
Mouse microglial cell line BV2 was obtained from CCTCC, and cultured in the DMEM culture medium supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO2. BV2 cells were proceeded with different treatments as follows: 1) Control group without isoflurane treatments or transfections; 2) Isoflurane group treated with 1.5% isoflurane for 6 hours; 3) si-BDNF-AS negative control (NC) group transfected with BDNF-AS siRNA NC (si-BDNF-AS NC, 5’-CCUCUCCACGCGCAGUACATT-3’) before isoflurane treatment; 4) si-BDNF-AS group transfected with BDNF-AS siRNA (si-BDNF-AS 5’-GGCTCACCAGTTGTTTGTT-3’) before treatment of isoflurane; 5) miR NC group co-transfected with si-BDNFAS and miR-214-3p NC (5’-CAGUACUUUUGUGUAGUACAA-3’) before treatment of isoflurane; 6) miR-214-3p inhibitor group co-transfected with si-BDNF-AS1 and miR-214-3p inhibitor (5’-ACUGCCUGUCUGUGCCUGCUGU-3’) before treatment of isoflurane.
Transfections were obtained from invitrogen and conducted with lipofectamine 3000 (Invitrogen, USA) at room temperature. After 48 hours of transfection, the transfected cells were available for the following experiments.
Oxidative stress evaluation
The concentration of malondialdehyde (MDA) and nitrite (NO2-), and activity of superoxide dismutase (SOD) were used to indirectly evaluate oxidative stress of BV2 cells. Concentrations of MDA and nitrite were analyzed with lipid peroxidation assay kit (Cayman, USA) and Griess reagent kit (Sigma, USA), and SOD activity was estimated using superoxide dismutase assay kit (Cayman, USA), according to the manufacturer’s instruction.
Dual-luciferase reporter assay
Binding sites between BDNF-AS and miR-214-3p predicted online (http://starbase.sysu.edu.cn) were cloned into pmirGLO vectors to establish a wild-type BDNF-AS (WT-BDNF-AS) vector, while mutant-type BDNF-AS (MT-BDNF-AS) vector was established by cloning mutant binding sites. The established vectors were co-transfected with miR-214-3p mimic (5’-ACAGCAGGCACAGACAGGCAGU-3’), miR-214-3p inhibitor, or miR NC into isoflurane-induced BV2 cells using lipofectamine 3000 (Invitrogen, USA). Luciferase activity of BDNF-AS was detected after 48 hours of transfection, and normalized to Renilla.
Grouping
The approval from the Guangzhou Red Cross Hospital had been obtained before the experiments. Male Sprague-Dawley rats were adopted in this study. All animals were maintained under controlled conditions at 23 ±2°C, with a humidity of 50 ±5%. Animals were allowed to adapt to the environment for 7 days with free access to food and drink.
Rats were randomly grouped with six rats of each group as follows: 1) Control group treated with an equal dose of stroke-physiological saline solution; 2) Isoflurane-induced group treated with 1.5% isoflurane for 6 hours with a flow rate of 2 l/min according to previous studies [17,24,28]; 3) BDNF-AS NC group injected with small interference RNA negative control (siRNA-NC) of BDNF-AS before anesthetization with isoflurane; 4) si-BDNF-AS group injected with siRNA of BDNF-AS before anesthetization with isoflurane; 5) Antagomir NC group injected with antagomir NC of miR-214-3p based on BDNF NC group or si-BDNF-AS group; 6) miR-214-3p antagomir group was injected with antagomir of miR-214-3p based on BDNF NC group or si-BDNF-AS group. Hippocampus tissues were collected after 24 hours of anesthetization for analyses.
Morris water maze task
A circular pool with a diameter of 1.5 m and a height of 0.5 m was used. The test was conducted with a water depth of 0.3 m at 20 ±2°C. The pool was divided into four quadrants, and an invisible platform was placed in the center of Northeast quadrant. Rats were trained daily to find the platform. Specifically, rats were placed randomly in one of the four quadrants facing the wall of the pool, and were allowed to swim for up to 60 sec to find the hidden platform and rest on it for 1 min. On the final day, the platform was removed to the probe position, and rats were allowed to find the probe position in 1 min. Escape latency, percentage of the distance, and swimming time in the target quadrant were recorded to assess the cognitive function of rats. Behavior data were collected and analyzed by Ethovision XT8 software (Noldus, The Netherlands).
BDNF-AS and miR-214-3p expression evaluation
The expression of BDNF-AS and miR-214-3p was evaluated with real-time PCR after isolation of total RNA from the hippocampus and BV2 cells, using Trizol reagent. cDNA was further generated with high-performance cDNA reverse transcription kit (Applied Biosystem, USA) for BDNF-AS, and TaqMan MicroRNA reverse transcription kit was applied for miR-214-3p. The generated cDNA was amplified and detected on Applied Biosystem 7500 real-time PCR system with GAPDH (for BDNF-AS) and miR-39 (for miR-214-3p) as internal reference. Sequences of used primers were as follows: BDNF-AS F: 5’-CATCCGAGGACAAGGTGGCTTG-3’, BDNF-AS R: 5’-GCCGAACTTTCTGGTCCTCATC-3’; miR-214-3p F: 5’-CAATACTGACAGCAGGCACA-3’, miR-214-3p R: 5’-TATGGTTGTTCACGACTCCTTCAC-3’; GAPDH F: 5’-AAGCCTGCCGGTGACTAAC-3’, GAPDH R: 5’-GCGCCCAATACGACCAAATC-3’; miR-39 F: 5’-UCACCGGGUGUAAAUCAGCUUG-3’, miR-39 R: 5’-TCACCGGGTGTAAATCAGCTTG-3’. Reaction conditions of PCR included all samples that were pre-heated for 2 min at 94°C, followed by denaturation at 94°C for 10 sec. Then, annealing was conducted at 60°C for 45 sec and amplified at 72°C for 90 sec (35 cycles). Relative expression levels were calculated with 2–DDCT method.
Pro-inflammation cytokines evaluation
Protein levels of pro-inflammation cytokines, including interleukin (IL)-1b, IL-6, IL-18, and tumor necrosis factor a (TNF-a) were evaluated with enzyme-linked immunosorbent assay. Tissues and cells were lysed and centrifugated at 5,000 g for 25 min, and supernatant was obtained. Protein levels were detected with enzyme-linked immunosorbent assay kits (Abcam, China) according to the manufacturer’s instruction.
Statistical analysis
All experiments were performed in triplicate with three independent determinations. All data were expressed as mean value ±SD. Differences were assessed with Student’s t-test or one-way ANOVA, followed by Turkey post-hoc test using SPSS version 26.0 software. Significance was marked with p < 0.05.

Results

Expression of BDNF-AS and miR-214-3p in isoflurane-induced BV2 cells
Compared with untreated BV2 cells, the treatment of isoflurane significantly improved the expression of BDNF-AS (p < 0.001, Fig. 1A), and suppressed the expression of miR-214-3p (p < 0.001, Fig. 1B). Meanwhile, the luciferase reporter results showed that over-expressing miR-214-3p dramatically inhibited the luciferase activity of BDNF-AS, and the opposite effect was observed in the BV2 cells with miR-214-3p knockdown (p < 0.001, Fig. 1C).
Effect of BDNF-AS and miR-214-3p on neurological inflammation and oxidative stress of BV2 cells
In the BV2 cells, the transfection of BDNF-AS siRNA dramatically reversed isoflurane-induced increase of BDNF-AS expression (p < 0.01, Fig. 2A). Similarly, the knockdown of BDNF-AS could prevent the miR-214-3p level from the inhibitory effect of isoflurane (p < 0.001), and co-transfection of its inhibitor was found to suppress the expression of miR-214-3p in BV2 cells (p < 0.01, Fig. 2B).
Isoflurane induced dramatic neurological inflammation in BV2 cells, behaving as the increasing levels of IL-1b, IL-6, IL-18, and TNF-a (p < 0.001, Fig. 3A). The knockdown of BDNF-AS was found to alleviate the neurological inflammation that was significantly reversed by the silencing of miR-214-3p (p < 0.01, Fig. 3A). Moreover, the isoflurane-treated cells showed relatively higher concentrations of MDA (Fig. 3B) and nitrite (Fig. 3C), and the decreasing activity of SOD (Fig. 3D) in comparison with untreated cells (p < 0.01). The reduced BDNF-AS could drop the MDA (Fig. 3B) and nitrite (Fig. 3C) concentrations and improve the activity of SOD (Fig. 3D) in the isoflurane-treated cells (p < 0.01), which was reversed by the knockdown of miR-214-3p (p < 0.01).
Effect of BDNF-AS and miR-214-3p on inflammation and cognitive function of isoflurane-induced rats
In isoflurane-induced rat models, the elevated expression of BDNF-AS (Fig. 4A) and reduced expression of miR-214-3p (Fig. 4B) were observed compared with the control group (p < 0.001), which was consistent with the abnormal expression levels in BV2 cells. The elevated BDNF-AS level in the isoflurane-induced rats was knocked down by the transfection of BDNF-AS siRNA, but the silencing of miR-214-3p showed no significant influence on the expression of BDNF-AS (p < 0.01, Fig. 4A). The reduced miR-214-3p caused by isoflurane was elevated by BDNF-AS silencing, which was reversed by miR-214-3p antagomir (p < 0.01, Fig. 4B).
Significant inflammation was observed in the isoflurane-treated rats with increasing levels of pro-inflammation cytokines, including IL-1b, IL-6, IL-18, and TNF-a (p < 0.001, Fig. 4C). The knockdown of BDNF-AS showed a significant inhibitory effect on the inflammation response of isoflurane-induced rats, which was attenuated by the silencing of miR-214-3p (p < 0.01, Fig. 4C).
In the Morris water maze task, the escape latency of rats in all groups was decreased with time. The treatment of isoflurane significantly reduced the escape latency (p < 0.01), while the knockdown of BDNF-AS recovered the escape latency of isoflurane-induced rats (p < 0.01), which was mediated by miR-214-3p p < 0.05, Fig. 5A). Additionally, isoflurane also shortened the spent time (Fig. 5B) and swimming time (Fig. 5C) in the target quadrant of rats (p < 0.01). Downregulation of BDNF-AS could protect rats from the im-pairment, which was crippled by the knockdown of miR-214-3p (p < 0.01, Fig. 5B and C).

Discussion

Microglia cells play vital roles in the immune of the central nervous system, and mediate secretion of inflammation cytokines, eliminate injured neurons, and therefore protect neurons from damage induced by environmental factors [6]. However, in response to specific stimuli, microglia would release pro-inflammatory factors, and further lead to neuro-inflammation, damage, and even neuron’s death [26]. It was reported that both inflammation and oxidative stress could promote the activation of microglia cells and even cause neurological impairment [12]. Previous studies demonstrated that the secretion of IL-1b and IL-18 by microglia cells could result in neuro-inflammation and cell death. With the wide application of isoflurane in clinics, different kind of harmful effects of isoflurane have been discovered, such as liver injury, ischemia-reperfusion damage, and neurological injury [15,18,32]. Herein, we found an enhanced levels of IL-1b, IL-6, TNF-a, and IL-18, and increasing oxidative stress in microglia cells induced by isoflurane, revealing the potential of isoflurane in causing neuro-inflammation.
Neuro-inflammation could contribute to neuronal dysfunction and impaired neurogenesis, and chronic neuro-inflammation manifests as cognitive disorders and post-operative delirium [1]. Prior studies reported that patients with the usage of isoflurane presented a high-risk of post-operative cognitive dysfunction, which was confirmed in rat models [3,5]. The isoflurane-induced rat model was established in the present study, and isoflurane-induced rats showed a deteriorating memory and cognitive ability compared with untreated rats. Meanwhile, isoflurane was also found to induce an inflammatory response in rats, which is consistent with the results in the microglia cells.
Some dysregulated molecules were suggested to regulate the inflammatory response and oxidative stress, and therefore mediate the isoflurane-induced impairment [7,19,23]. BDNF-AS is an antisense lncRNA that repressed the expression of BDNF, which has been identified as a promising therapeutic target of various neurological disorders, such as Parkinson’s disease, schizophrenia, and Alzheimer’s disease. The significance of BDNF-AS in human disease has also been widely reported [10]. For instance, the downregulation of BDNF-AS in prostate and breast cancer was disclosed to correlate with patients’ poor outcomes and malignant development [14,16]. In some neuro-degenerative diseases, such as Huntington’s disease, the dysregulation of BDNF-AS was observed. BDNF-AS was also reported to mediate the mitigating effect of lithium on spinal cord injury through attenuating neuron apoptosis and inflammation [27]. Here, we observed a significant upregulation of BDNF-AS in the isoflurane-induced microglia cells and rat models.The knockdown of BDNF-AS could dramatically suppress neuro-inflammation and oxidative stress of microalga cells. Moreover, in the isoflurane-induced rat models, silencing BDNF-AS showed a significant protective effect that alleviated inflammatory response and recovered the cognitive and memory ability of rats. All these results indicated the involvement of BDNF-AS in the nerve destroying effect of isoflurane.
In mechanism, lncRNAs modulate downstream ceRNAs, such as miRNAs, to perform their function. The regulation of miR-214-3p by BDNF-AS was reported in esophageal cancer, where miR-214-3p mediated the tumor suppressor role of BDNF-AS in cell proliferation, metastasis, and EMT processes [31]. miR-214-3p was previously indicated to be abnormally expressed in neuro-pathological cognitive disorders, and to participate in the development of correlated diseases. For example, miR-214-3p reduced hippocampal neuron apoptosis and inhibited autophagy, and therefore alleviated cognitive defects in Alzheimer’s disease [30]. As the ceRNA of lncRNA BACE1-AS, miR-214-3p reversed the protective effect of lncRNA BACE1-AS on Alzheimer’s disease via regulating ATG5 [11]. The interaction between BDNF-AS and miR-214-3p was also confirmed in the microglia cells. miR-214-3p was found to negatively regulate the luciferase activity of BDNF-AS, and BDNF-AS negatively regulated the expression of miR-214-3p. Along with with its’ role in esophageal cancer, miR-214-3p reversed the protective effect of BDNF-AS knockdown on isoflurane-induced neuro-inflammation and cognitive impairment.
According to the above results, it can be concluded that isoflurane could induce neuro-inflammation and cognitive and learning dysfunctions. The suppression of BDNF-AS alleviated neuro-inflammation and oxidative stress, and improved cognitive and learning impairment induced by isoflurane through sponging miR-214-3p.

Funding

This study was funded by the Guangzhou Health Science and Technology Project (No.: 20221A011020).

Disclosure

The authors report no conflict of interest.
References
1. Alam A, Hana Z, Jin Z, Suen KC, Ma D. Surgery, neuroinflammation and cognitive impairment. EBioMedicine 2018; 37: 547-556.
2. Bahlakeh G, Gorji A, Soltani H, Ghadiri T. MicroRNA alterations in neuropathologic cognitive disorders with an emphasis on dementia: Lessons from animal models. J Cell Physiol 2021; 236: 806-823.
3. Belrose JC, Noppens RR. Anesthesiology and cognitive impairment: a narrative review of current clinical literature. BMC Anesthesiol 2019; 19: 241.
4. Burchell SR, Dixon BJ, Tang J, Zhang JH. Isoflurane provides neuroprotection in neonatal hypoxic ischemic brain injury. J Investig Med 2013; 61: 1078-1083.
5. Cao L, Li L, Lin D, Zuo Z. Isoflurane induces learning impairment that is mediated by interleukin 1beta in rodents. PLoS One 2012; 7: e51431.
6. Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol 2017; 35: 441-468.
7. Colucci-D’Amato L, Speranza L, Volpicelli F. Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int J Mol Sci 2020; 21: 7777.
8. Ding Y, Luan W, Shen X, Wang Z, Cao Y. LncRNA BDNF-AS as ceRNA regulates the miR-9-5p/BACE1 pathway affecting neurotoxicity in Alzheimer’s disease. Arch Gerontol Geriatr 2022; 99: 104614.
9. Fan Y, Zhao X, Lu K, Cheng G. LncRNA BDNF-AS promotes autophagy and apoptosis in MPTP-induced Parkinson’s disease via ablating microRNA-125b-5p. Brain Res Bull 2020; 157: 119-127.
10. Ghafouri-Fard S, Khoshbakht T, Taheri M, Ghanbari M. A concise review on the role of BDNF-AS in human disorders. Biomed Pharmacother 2021; 142: 112051.
11. He W, Chi S, Jin X, Lu J, Zheng W, Yan J, Zhang D. Long Non-Coding RNA BACE1-AS modulates isoflurane-induced neurotoxicity to Alzheimer’s disease through sponging miR-214-3p. Neurochem Res 2020; 45: 2324-2335.
12. Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener 2020; 9: 42.
13. Lang XE, Wang X, Jin JH. Mechanisms of cardioprotection by isoflurane against I/R injury. Front Biosci (Landmark Ed.) 2013; 18: 387-393.
14. Li W, Dou Z, We S, Zhu Z, Pan D, Jia Z, Liu H, Wang X, Yu G. Long noncoding RNA BDNF-AS is associated with clinical outcomes and has functional role in human prostate cancer. Biomed Pharmacother 2018; 102: 1105-1110.
15. Li X, Yao Q, Li R, Jin Y. Isoflurane induces liver injury by modulating the expression of miR-125a-5p. Clin Res Hepatol Gastroenterol 2021; 45: 101732.
16. Lin X, Dinglin X, Cao S, Zheng S, Wu C, Chen W, Li Q, Hu Q, Zheng F, Wu Z, Lin DC, Yao Y, Xu X, Xie Z, Liu Q, Yao H, Hu H. Enhancer-driven lncRNA BDNF-AS induces endocrine resistance and malignant progression of breast cancer through the RNH1/TRIM21/mTOR cascade. Cell Rep 2020; 31: 107753.
17. Liu F, Qiu F, Chen H. miR-124-3p ameliorates isoflurane-induced learning and memory impairment via targeting STAT3 and inhibiting neuroinflammation. Neuroimmunomodulation 2021; 28: 248-254.
18. Liu G, Qiao S, Yu Y, Zhang X, Li N, Hou D. Isoflurane improves cerebral ischemia-reperfusion injury in rats via activating MAPK signaling pathway. J Neurosurg Sci 2021; 65: 80-81.
19. Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol 2014; 220: 223-250.
20. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006; 15 Spec No 1: R17-29.
21. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10: 155-159.
22. Ni C, Li C, Dong Y, Guo X, Zhang Y, Xie Z. Anesthetic isoflurane induces DNA damage through oxidative stress and p53 pathway. Mol Neurobiol 2017; 54: 3591-3605.
23. Palasz E, Wysocka A, Gasiorowska A, Chalimoniuk M, Niewiadomski W, Niewiadomska G. BDNF as a promising therapeutic agent in Parkinson’s disease. Int J Mol Sci 2020; 21: 1170.
24. Que Y, Zhang F, Peng J, Zhang Z, Zhang D, He M. Repeated isoflurane exposures of neonatal rats contribute to cognitive dysfunction in juvenile animals: the role of miR-497 in isoflurane-induced neurotoxicity. Folia Histochem Cytobiol 2021; 59: 114-123.
25. Riva P, Ratti A, Venturin M. The long non-coding RNAs in neurodegenerative diseases: novel mechanisms of pathogenesis. Curr Alzheimer Res 2016; 13: 1219-1231.
26. Subhramanyam CS, Wang C, Hu Q, Dheen ST. Microglia-mediated neuroinflammation in neurodegenerative diseases. Semin Cell Dev Biol 2019; 94: 112-120.
27. Wang F, Chang S, Li J, Wang D, Li H, He X. Lithium alleviated spinal cord injury (SCI)-induced apoptosis and inflammation in rats via BDNF-AS/miR-9-5p axis. Cell Tissue Res 2021; 384: 301-312.
28. Wang X, Shan Y, Tang Z, Gao L, Liu H. Neuroprotective effects of dexmedetomidine against isoflurane-induced neuronal injury via glutamate regulation in neonatal rats. Drug Des Devel Ther 2019; 13: 153-160.
29. Yu X, Zhao Q, Wang X, Zhang J, Wang X. Gambogenic acid induces proteasomal degradation of CIP2A and sensitizes hepatocellular carcinoma to anticancer agents. Oncol Rep 2016; 36: 3611-3618.
30. Zhang Y, Li Q, Liu C, Gao S, Ping H, Wang J, Wang P. MiR-214-3p attenuates cognition defects via the inhibition of autophagy in SAMP8 mouse model of sporadic Alzheimer’s disease. Neurotoxicology 2016; 56: 139-149.
31. Zhao H, Diao C, Wang X, Xie Y, Liu Y, Gao X, Han J, Li S. LncRNA BDNF-AS inhibits proliferation, migration, invasion and EMT in oesophageal cancer cells by targeting miR-214. J Cell Mol Med 2018; 22: 3729-3739.
32. Zhu S, Wang Z, Yu J, Yin L, Zhu A. Atractylenolide III alleviates isoflurane-induced injury in rat hippocampal neurons by activating the PI3K/Akt/mTOR pathway. J Food Biochem 2021; 45: e13892.
Copyright: © 2023 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.